81311-87-7

Upstream product

• 81311-76-4 (4-Amino-phenyl)-cyclohexyl-acetic acid 
• 76618-89-8 2-Cyclohexyl-2-(p-methoxyphenyl)essigsaeure 
• 953-91-3 cyclohexyl tosylate 
• 108-93-0 cyclohexanol 
• 81311-75-3 cyclohexyl-(4-nitro-phenyl)-acetic acid 

Downstream Products

• 81311-79-7 (4-Benzyloxy-phenyl)-cyclohexyl-acetic acid 
• 81311-78-6 (4-Benzyloxy-phenyl)-cyclohexyl-acetic acid methyl ester 
• 81311-80-0 (4-Benzyloxy-phenyl)-cyclohexyl-acetyl chloride 

Relevant academic research and scientific papers

Design, synthesis, and functional assessment of Cmpd-15 derivatives as negative allosteric modulators for the β2-adrenergic receptor

The β2-adrenergic receptor (β2AR), a G protein-coupled receptor, is an important therapeutic target. We recently described Cmpd-15, the first small molecule negative allosteric modulator (NAM) for the β2AR. Herein we report in details the design, synthesis and structure-activity relationships (SAR) of seven Cmpd-15 derivatives. Furthermore, we provide in a dose-response paradigm, the details of the effects of these derivatives in modulating agonist-induced β2AR activities (G-protein-mediated cAMP production and β-arrestin recruitment to the receptor) as well as the binding affinity of an orthosteric agonist in radio-ligand competition binding assay. Our results show that some modifications, including removal of the formamide group in the para-formamido phenylalanine region and bromine in the meta-bromobenzyl methylbenzamide region caused dramatic reduction in the functional activity of Cmpd-15. These SAR results provide valuable insights into the mechanism of action of the NAM Cmpd-15 as well as the basis for future development of more potent and selective modulators for the β2AR based on the chemical scaffold of Cmpd-15.

Synthesis and Cardiovascular Activity of a New Series of Cyclohexylaralkylamine Derivatives Related to Perhexiline

A series of 24 cyclohexylaralkylamine derivatives related to perhexilene has been synthesized and screened for cardiovascular activity.All the compounds contained an exocyclic amine which was substituted either by an alkyl, cycloalkyl, or aralkyl group.In the hope of further reducing toxicity, the synthesis of p-tolyl- and p-hydroxyphenyl derivatives 23 and 24 was undertaken.The effect of separating the cyclohexylamine moiety with respect to the aromatic nucleus has been systematically examined.The pharmacological investigations were directed to a search for compounds having an activity better than perhexiline according to the following order of criteria: (1) α-adrenolytic activity; (2) increase of coronary blood flow; (3) calcium antagonism.Several compounds were more potent and exhibited lower toxicity than perhexiline.Further detailed pharmacological investigations (tension time index and decreased cardiac work) have led to the selection of N,2-dicyclohexyl-2-phenethylamine (3) for clinical trials, which are now under way.